Indo Amines Limited

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, UPL.BO has a market cap of 501.9B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while UPL.BO trades at ₹581.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas UPL.BO's P/E ratio is 28.38. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to UPL.BO's ROE of +0.05%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to UPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check UPL.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, FLUOROCHEM.NS has a market cap of 355.3B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while FLUOROCHEM.NS trades at ₹3,164.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas FLUOROCHEM.NS's P/E ratio is 54.22. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to FLUOROCHEM.NS's ROE of +0.09%. Regarding short-term risk, INDOAMIN.BO is more volatile compared to FLUOROCHEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.BO.Check FLUOROCHEM.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, DEEPAKNI.BO has a market cap of 332.3B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while DEEPAKNI.BO trades at ₹2,436.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas DEEPAKNI.BO's P/E ratio is 57.46. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to DEEPAKNI.BO's ROE of +0.06%. Regarding short-term risk, INDOAMIN.BO is more volatile compared to DEEPAKNI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.BO.Check DEEPAKNI.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, NAVINFLUOR.NS has a market cap of 309.2B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while NAVINFLUOR.NS trades at ₹5,774.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas NAVINFLUOR.NS's P/E ratio is 55.95. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to NAVINFLUOR.NS's ROE of +0.19%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to NAVINFLUOR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check NAVINFLUOR.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, NAVINFLUOR.BO has a market cap of 308.9B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while NAVINFLUOR.BO trades at ₹5,790.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas NAVINFLUOR.BO's P/E ratio is 55.95. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to NAVINFLUOR.BO's ROE of +0.19%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to NAVINFLUOR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check NAVINFLUOR.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, BAYERCROP.BO has a market cap of 212.6B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while BAYERCROP.BO trades at ₹4,607.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas BAYERCROP.BO's P/E ratio is 31.69. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to BAYERCROP.BO's ROE of +0.23%. Regarding short-term risk, INDOAMIN.BO is more volatile compared to BAYERCROP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.BO.Check BAYERCROP.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, DEEPAKNTR.BO has a market cap of 184.5B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while DEEPAKNTR.BO trades at ₹1,321.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas DEEPAKNTR.BO's P/E ratio is 34.56. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to DEEPAKNTR.BO's ROE of +0.10%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to DEEPAKNTR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check DEEPAKNTR.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, DEEPAKNTR.NS has a market cap of 184.4B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while DEEPAKNTR.NS trades at ₹1,337.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas DEEPAKNTR.NS's P/E ratio is 34.57. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to DEEPAKNTR.NS's ROE of +0.10%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to DEEPAKNTR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check DEEPAKNTR.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, TATACHEM.BO has a market cap of 154.6B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while TATACHEM.BO trades at ₹613.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas TATACHEM.BO's P/E ratio is 94.96. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to TATACHEM.BO's ROE of +0.01%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to TATACHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check TATACHEM.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, TATACHEM.NS has a market cap of 154.6B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while TATACHEM.NS trades at ₹621.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas TATACHEM.NS's P/E ratio is 95.40. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to TATACHEM.NS's ROE of +0.01%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to TATACHEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check TATACHEM.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, SPLPETRO.NS has a market cap of 138.9B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while SPLPETRO.NS trades at ₹720.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas SPLPETRO.NS's P/E ratio is 51.78. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to SPLPETRO.NS's ROE of +0.12%. Regarding short-term risk, INDOAMIN.BO is more volatile compared to SPLPETRO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.BO.Check SPLPETRO.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, DEEPAKFERT.NS has a market cap of 124.8B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while DEEPAKFERT.NS trades at ₹967.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas DEEPAKFERT.NS's P/E ratio is 14.25. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to DEEPAKFERT.NS's ROE of +0.14%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to DEEPAKFERT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check DEEPAKFERT.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, DEEPAKFERT.BO has a market cap of 124.7B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while DEEPAKFERT.BO trades at ₹966.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas DEEPAKFERT.BO's P/E ratio is 14.26. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to DEEPAKFERT.BO's ROE of +0.14%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to DEEPAKFERT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check DEEPAKFERT.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, ACI.NS has a market cap of 71.8B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while ACI.NS trades at ₹574.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas ACI.NS's P/E ratio is 49.01. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to ACI.NS's ROE of +0.08%. Regarding short-term risk, INDOAMIN.BO is more volatile compared to ACI.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.BO.Check ACI.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, ACI.BO has a market cap of 71.7B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while ACI.BO trades at ₹574.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas ACI.BO's P/E ratio is 48.99. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to ACI.BO's ROE of +0.08%. Regarding short-term risk, INDOAMIN.BO is more volatile compared to ACI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.BO.Check ACI.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, INDIAGLYCO.NS has a market cap of 59.2B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while INDIAGLYCO.NS trades at ₹868.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas INDIAGLYCO.NS's P/E ratio is 20.44. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to INDIAGLYCO.NS's ROE of +0.12%. Regarding short-term risk, INDOAMIN.BO is more volatile compared to INDIAGLYCO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.BO.Check INDIAGLYCO.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, INDIAGLYCO.BO has a market cap of 59.1B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while INDIAGLYCO.BO trades at ₹866.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas INDIAGLYCO.BO's P/E ratio is 21.08. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to INDIAGLYCO.BO's ROE of +0.12%. Regarding short-term risk, INDOAMIN.BO is more volatile compared to INDIAGLYCO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.BO.Check INDIAGLYCO.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, GNFC.BO has a market cap of 57.5B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while GNFC.BO trades at ₹387.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas GNFC.BO's P/E ratio is 9.03. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to GNFC.BO's ROE of +0.07%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to GNFC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check GNFC.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, GNFC.NS has a market cap of 57.5B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while GNFC.NS trades at ₹389.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas GNFC.NS's P/E ratio is 9.22. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to GNFC.NS's ROE of +0.07%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to GNFC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check GNFC.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, MFL.NS has a market cap of 44.1B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while MFL.NS trades at ₹1,062.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas MFL.NS's P/E ratio is 15.94. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to MFL.NS's ROE of +0.39%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to MFL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check MFL.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, GUJALKALI.BO has a market cap of 43.5B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while GUJALKALI.BO trades at ₹588.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas GUJALKALI.BO's P/E ratio is -497.39. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to GUJALKALI.BO's ROE of -0.00%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to GUJALKALI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check GUJALKALI.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, GUJALKALI.NS has a market cap of 43.4B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while GUJALKALI.NS trades at ₹586.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas GUJALKALI.NS's P/E ratio is -496.89. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to GUJALKALI.NS's ROE of -0.00%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to GUJALKALI.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check GUJALKALI.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, CHEMPLASTS.NS has a market cap of 41.2B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while CHEMPLASTS.NS trades at ₹254.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas CHEMPLASTS.NS's P/E ratio is -14.41. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to CHEMPLASTS.NS's ROE of -0.15%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to CHEMPLASTS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check CHEMPLASTS.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, CHEMPLASTS.BO has a market cap of 41.1B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while CHEMPLASTS.BO trades at ₹254.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas CHEMPLASTS.BO's P/E ratio is -14.40. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to CHEMPLASTS.BO's ROE of -0.15%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to CHEMPLASTS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check CHEMPLASTS.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, GHCL.NS has a market cap of 40.9B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while GHCL.NS trades at ₹444.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas GHCL.NS's P/E ratio is 8.37. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to GHCL.NS's ROE of +0.15%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to GHCL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check GHCL.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, GHCL.BO has a market cap of 40.9B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while GHCL.BO trades at ₹442.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas GHCL.BO's P/E ratio is 8.36. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to GHCL.BO's ROE of +0.15%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to GHCL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check GHCL.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, RAIN.NS has a market cap of 38.6B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while RAIN.NS trades at ₹110.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas RAIN.NS's P/E ratio is 91.17. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to RAIN.NS's ROE of +0.01%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to RAIN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check RAIN.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, RAIN.BO has a market cap of 38.6B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while RAIN.BO trades at ₹110.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas RAIN.BO's P/E ratio is 91.15. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to RAIN.BO's ROE of +0.01%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to RAIN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check RAIN.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, EPIGRAL.BO has a market cap of 37.7B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while EPIGRAL.BO trades at ₹854.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas EPIGRAL.BO's P/E ratio is 11.16. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to EPIGRAL.BO's ROE of +0.18%. Regarding short-term risk, INDOAMIN.BO is more volatile compared to EPIGRAL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.BO.Check EPIGRAL.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, EPIGRAL.NS has a market cap of 37.5B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while EPIGRAL.NS trades at ₹857.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas EPIGRAL.NS's P/E ratio is 11.10. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to EPIGRAL.NS's ROE of +0.18%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to EPIGRAL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check EPIGRAL.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, MEGH.NS has a market cap of 35.3B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while MEGH.NS trades at ₹139.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas MEGH.NS's P/E ratio is 15.63. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to MEGH.NS's ROE of +0.16%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to MEGH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check MEGH.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, STYRENIX.NS has a market cap of 32.5B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while STYRENIX.NS trades at ₹1,820.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas STYRENIX.NS's P/E ratio is 19.91. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to STYRENIX.NS's ROE of +0.14%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to STYRENIX.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check STYRENIX.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, STYRENIX.BO has a market cap of 32.4B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while STYRENIX.BO trades at ₹1,815.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas STYRENIX.BO's P/E ratio is 19.56. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to STYRENIX.BO's ROE of +0.14%. Regarding short-term risk, INDOAMIN.BO is more volatile compared to STYRENIX.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.BO.Check STYRENIX.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, FOSECOIND.NS has a market cap of 29.5B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while FOSECOIND.NS trades at ₹4,580.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas FOSECOIND.NS's P/E ratio is 41.90. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to FOSECOIND.NS's ROE of +0.14%. Regarding short-term risk, INDOAMIN.BO is more volatile compared to FOSECOIND.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.BO.Check FOSECOIND.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, FOSECOIND.BO has a market cap of 29.5B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while FOSECOIND.BO trades at ₹4,596.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas FOSECOIND.BO's P/E ratio is 37.24. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to FOSECOIND.BO's ROE of +0.14%. Regarding short-term risk, INDOAMIN.BO is more volatile compared to FOSECOIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.BO.Check FOSECOIND.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, RPEL.BO has a market cap of 28.9B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while RPEL.BO trades at ₹611.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas RPEL.BO's P/E ratio is 58.16. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to RPEL.BO's ROE of +0.26%. Regarding short-term risk, INDOAMIN.BO is more volatile compared to RPEL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.BO.Check RPEL.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, RPEL.NS has a market cap of 28.7B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while RPEL.NS trades at ₹618.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas RPEL.NS's P/E ratio is 57.93. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to RPEL.NS's ROE of +0.24%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to RPEL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check RPEL.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, ELLEN.NS has a market cap of 28.7B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while ELLEN.NS trades at ₹198.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas ELLEN.NS's P/E ratio is N/A. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to ELLEN.NS's ROE of +0.09%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to ELLEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check ELLEN.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, DDEVPLASTIK.BO has a market cap of 27.2B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while DDEVPLASTIK.BO trades at ₹262.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas DDEVPLASTIK.BO's P/E ratio is 14.39. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to DDEVPLASTIK.BO's ROE of +0.18%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to DDEVPLASTIK.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check DDEVPLASTIK.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, BEPL.NS has a market cap of 21.5B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while BEPL.NS trades at ₹85.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas BEPL.NS's P/E ratio is 12.78. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to BEPL.NS's ROE of +0.17%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to BEPL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check BEPL.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, BEPL.BO has a market cap of 21.4B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while BEPL.BO trades at ₹85.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas BEPL.BO's P/E ratio is 12.87. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to BEPL.BO's ROE of +0.17%. Regarding short-term risk, INDOAMIN.BO is more volatile compared to BEPL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.BO.Check BEPL.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, GODAVARIB.NS has a market cap of 16.1B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while GODAVARIB.NS trades at ₹310.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas GODAVARIB.NS's P/E ratio is 45.85. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to GODAVARIB.NS's ROE of +0.03%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to GODAVARIB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check GODAVARIB.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, INEOSSTYRO.NS has a market cap of 14.2B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while INEOSSTYRO.NS trades at ₹807.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas INEOSSTYRO.NS's P/E ratio is 11.53. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to INEOSSTYRO.NS's ROE of +0.23%. Regarding short-term risk, INDOAMIN.BO is more volatile compared to INEOSSTYRO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.BO.Check INEOSSTYRO.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, SANSTAR.NS has a market cap of 13.9B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while SANSTAR.NS trades at ₹75.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas SANSTAR.NS's P/E ratio is 73.23. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to SANSTAR.NS's ROE of +0.03%. Regarding short-term risk, INDOAMIN.BO is more volatile compared to SANSTAR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.BO.Check SANSTAR.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, DCW.NS has a market cap of 12.1B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while DCW.NS trades at ₹39.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas DCW.NS's P/E ratio is 29.13. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to DCW.NS's ROE of +0.04%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to DCW.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check DCW.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, DCW.BO has a market cap of 12.1B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while DCW.BO trades at ₹39.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas DCW.BO's P/E ratio is 24.28. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to DCW.BO's ROE of +0.04%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to DCW.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check DCW.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, PUNJABCHEM.NS has a market cap of 11.4B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while PUNJABCHEM.NS trades at ₹922.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas PUNJABCHEM.NS's P/E ratio is 18.98. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to PUNJABCHEM.NS's ROE of +0.16%. Regarding short-term risk, INDOAMIN.BO is more volatile compared to PUNJABCHEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.BO.Check PUNJABCHEM.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, PUNJABCHEM.BO has a market cap of 11.4B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while PUNJABCHEM.BO trades at ₹927.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas PUNJABCHEM.BO's P/E ratio is 18.91. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to PUNJABCHEM.BO's ROE of +0.16%. Regarding short-term risk, INDOAMIN.BO is more volatile compared to PUNJABCHEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.BO.Check PUNJABCHEM.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, IGPL.BO has a market cap of 11.1B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while IGPL.BO trades at ₹347.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas IGPL.BO's P/E ratio is 34.26. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to IGPL.BO's ROE of -0.01%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to IGPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check IGPL.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, ANDHRSUGAR.BO has a market cap of 9.9B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while ANDHRSUGAR.BO trades at ₹71.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas ANDHRSUGAR.BO's P/E ratio is 11.90. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to ANDHRSUGAR.BO's ROE of +0.05%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to ANDHRSUGAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check ANDHRSUGAR.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, ANDHRSUGAR.NS has a market cap of 9.9B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while ANDHRSUGAR.NS trades at ₹72.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas ANDHRSUGAR.NS's P/E ratio is 11.87. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to ANDHRSUGAR.NS's ROE of +0.05%. Regarding short-term risk, INDOAMIN.BO is more volatile compared to ANDHRSUGAR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.BO.Check ANDHRSUGAR.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, GULPOLY.NS has a market cap of 9.3B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while GULPOLY.NS trades at ₹147.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas GULPOLY.NS's P/E ratio is 12.12. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to GULPOLY.NS's ROE of +0.12%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to GULPOLY.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check GULPOLY.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, GULPOLY.BO has a market cap of 9.3B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while GULPOLY.BO trades at ₹146.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas GULPOLY.BO's P/E ratio is 12.14. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to GULPOLY.BO's ROE of +0.12%. Regarding short-term risk, INDOAMIN.BO is more volatile compared to GULPOLY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.BO.Check GULPOLY.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, ZUARI.BO has a market cap of 8.2B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while ZUARI.BO trades at ₹192.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas ZUARI.BO's P/E ratio is 0.86. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to ZUARI.BO's ROE of +0.41%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to ZUARI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check ZUARI.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, ORIENTCQ.BO has a market cap of 8.1B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while ORIENTCQ.BO trades at ₹810.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas ORIENTCQ.BO's P/E ratio is 15.88. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to ORIENTCQ.BO's ROE of +0.01%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to ORIENTCQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check ORIENTCQ.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, INDOBORAX.NS has a market cap of 7.8B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while INDOBORAX.NS trades at ₹245.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas INDOBORAX.NS's P/E ratio is 17.02. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to INDOBORAX.NS's ROE of +0.14%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to INDOBORAX.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check INDOBORAX.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, INDOBORAX.BO has a market cap of 7.8B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while INDOBORAX.BO trades at ₹243.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas INDOBORAX.BO's P/E ratio is 16.99. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to INDOBORAX.BO's ROE of +0.14%. Regarding short-term risk, INDOAMIN.BO is more volatile compared to INDOBORAX.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.BO.Check INDOBORAX.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, A1L.BO has a market cap of 7.7B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while A1L.BO trades at ₹15.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas A1L.BO's P/E ratio is 208.50. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to A1L.BO's ROE of +0.03%. Regarding short-term risk, INDOAMIN.BO is more volatile compared to A1L.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.BO.Check A1L.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, GEMAROMA.NS has a market cap of 7.6B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while GEMAROMA.NS trades at ₹148.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas GEMAROMA.NS's P/E ratio is 27.04. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to GEMAROMA.NS's ROE of +0.08%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to GEMAROMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check GEMAROMA.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, AMNPLST.BO has a market cap of 7.5B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while AMNPLST.BO trades at ₹134.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas AMNPLST.BO's P/E ratio is 22.16. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to AMNPLST.BO's ROE of +0.13%. Regarding short-term risk, INDOAMIN.BO is more volatile compared to AMNPLST.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.BO.Check AMNPLST.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, AMNPLST.NS has a market cap of 7.5B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while AMNPLST.NS trades at ₹133.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas AMNPLST.NS's P/E ratio is 22.05. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to AMNPLST.NS's ROE of +0.13%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to AMNPLST.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check AMNPLST.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, SRHHYPOLTD.BO has a market cap of 7.1B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while SRHHYPOLTD.BO trades at ₹409.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas SRHHYPOLTD.BO's P/E ratio is 7.64. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to SRHHYPOLTD.BO's ROE of +0.10%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to SRHHYPOLTD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check SRHHYPOLTD.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, SRHHYPOLTD.NS has a market cap of 7.1B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while SRHHYPOLTD.NS trades at ₹407.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas SRHHYPOLTD.NS's P/E ratio is 7.57. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to SRHHYPOLTD.NS's ROE of +0.10%. Regarding short-term risk, INDOAMIN.BO is more volatile compared to SRHHYPOLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.BO.Check SRHHYPOLTD.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, INDOAMIN.NS has a market cap of 6.8B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while INDOAMIN.NS trades at ₹93.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas INDOAMIN.NS's P/E ratio is 9.56. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to INDOAMIN.NS's ROE of +0.22%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to INDOAMIN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check INDOAMIN.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, UNIENTER.NS has a market cap of 6.6B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while UNIENTER.NS trades at ₹96.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas UNIENTER.NS's P/E ratio is 33.07. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to UNIENTER.NS's ROE of +0.01%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to UNIENTER.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check UNIENTER.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, VALIANTORG.BO has a market cap of 6.5B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while VALIANTORG.BO trades at ₹219.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas VALIANTORG.BO's P/E ratio is 27.12. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to VALIANTORG.BO's ROE of +0.03%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to VALIANTORG.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check VALIANTORG.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, VALIANTORG.NS has a market cap of 6.5B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while VALIANTORG.NS trades at ₹221.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas VALIANTORG.NS's P/E ratio is 26.93. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to VALIANTORG.NS's ROE of +0.03%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to VALIANTORG.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check VALIANTORG.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, NATPEROX.BO has a market cap of 6B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while NATPEROX.BO trades at ₹1,040.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas NATPEROX.BO's P/E ratio is 399.75. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to NATPEROX.BO's ROE of -0.02%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to NATPEROX.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check NATPEROX.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, SUNSHIEL.BO has a market cap of 5.6B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while SUNSHIEL.BO trades at ₹759.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas SUNSHIEL.BO's P/E ratio is 23.51. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to SUNSHIEL.BO's ROE of +0.25%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to SUNSHIEL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check SUNSHIEL.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, DMCC.NS has a market cap of 5.3B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while DMCC.NS trades at ₹206.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas DMCC.NS's P/E ratio is 20.17. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to DMCC.NS's ROE of +0.12%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to DMCC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check DMCC.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, DMCC.BO has a market cap of 5.3B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while DMCC.BO trades at ₹208.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas DMCC.BO's P/E ratio is 20.13. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to DMCC.BO's ROE of +0.12%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to DMCC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check DMCC.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, PRIMO.NS has a market cap of 4.6B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while PRIMO.NS trades at ₹19.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas PRIMO.NS's P/E ratio is 79.79. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to PRIMO.NS's ROE of +0.02%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to PRIMO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check PRIMO.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, ARIES.BO has a market cap of 4.4B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while ARIES.BO trades at ₹334.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas ARIES.BO's P/E ratio is 10.17. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to ARIES.BO's ROE of +0.15%. Regarding short-term risk, INDOAMIN.BO is more volatile compared to ARIES.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.BO.Check ARIES.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, OCCLLTD.NS has a market cap of 4.3B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while OCCLLTD.NS trades at ₹85.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas OCCLLTD.NS's P/E ratio is 11.71. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to OCCLLTD.NS's ROE of +0.09%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to OCCLLTD.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check OCCLLTD.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, SHIVALIK.BO has a market cap of 3.6B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while SHIVALIK.BO trades at ₹233.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas SHIVALIK.BO's P/E ratio is 31.37. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to SHIVALIK.BO's ROE of +0.02%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to SHIVALIK.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check SHIVALIK.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, NAPEROL.BO has a market cap of 3.1B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while NAPEROL.BO trades at ₹530.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas NAPEROL.BO's P/E ratio is 33.84. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to NAPEROL.BO's ROE of -0.02%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to NAPEROL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check NAPEROL.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, DCMSRMIND.BO has a market cap of 3.1B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while DCMSRMIND.BO trades at ₹175.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas DCMSRMIND.BO's P/E ratio is 3.63. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to DCMSRMIND.BO's ROE of +0.05%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to DCMSRMIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check DCMSRMIND.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, LORDSCHLO.NS has a market cap of 3B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while LORDSCHLO.NS trades at ₹120.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas LORDSCHLO.NS's P/E ratio is 11.76. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to LORDSCHLO.NS's ROE of +0.14%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to LORDSCHLO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check LORDSCHLO.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, LORDSCHLO.BO has a market cap of 3B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while LORDSCHLO.BO trades at ₹120.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas LORDSCHLO.BO's P/E ratio is 11.74. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to LORDSCHLO.BO's ROE of +0.14%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to LORDSCHLO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check LORDSCHLO.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, KANORICHEM.NS has a market cap of 2.7B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while KANORICHEM.NS trades at ₹60.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas KANORICHEM.NS's P/E ratio is -3.61. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to KANORICHEM.NS's ROE of -0.08%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to KANORICHEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check KANORICHEM.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, KANORICHEM.BO has a market cap of 2.7B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while KANORICHEM.BO trades at ₹60.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas KANORICHEM.BO's P/E ratio is -3.58. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to KANORICHEM.BO's ROE of -0.08%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to KANORICHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check KANORICHEM.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, DIAMINESQ.NS has a market cap of 2.4B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while DIAMINESQ.NS trades at ₹242.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas DIAMINESQ.NS's P/E ratio is -25.94. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to DIAMINESQ.NS's ROE of -0.06%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to DIAMINESQ.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check DIAMINESQ.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, DIAMINESQ.BO has a market cap of 2.4B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while DIAMINESQ.BO trades at ₹238.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas DIAMINESQ.BO's P/E ratio is -25.78. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to DIAMINESQ.BO's ROE of -0.06%. Regarding short-term risk, INDOAMIN.BO is more volatile compared to DIAMINESQ.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.BO.Check DIAMINESQ.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, OCCL.NS has a market cap of 2.3B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while OCCL.NS trades at ₹233.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas OCCL.NS's P/E ratio is 77.52. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to OCCL.NS's ROE of +0.02%. Regarding short-term risk, INDOAMIN.BO is more volatile compared to OCCL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.BO.Check OCCL.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, INDGELA.BO has a market cap of 2.2B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while INDGELA.BO trades at ₹318.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas INDGELA.BO's P/E ratio is 8.49. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to INDGELA.BO's ROE of +0.15%. Regarding short-term risk, INDOAMIN.BO is more volatile compared to INDGELA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.BO.Check INDGELA.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, JAYSYNTH.BO has a market cap of 1.5B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while JAYSYNTH.BO trades at ₹11.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas JAYSYNTH.BO's P/E ratio is 12.06. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to JAYSYNTH.BO's ROE of N/A. Regarding short-term risk, INDOAMIN.BO is less volatile compared to JAYSYNTH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check JAYSYNTH.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, ISHANCH.NS has a market cap of 1.3B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while ISHANCH.NS trades at ₹50.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas ISHANCH.NS's P/E ratio is -11.85. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to ISHANCH.NS's ROE of -0.08%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to ISHANCH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check ISHANCH.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, PAUSHAKLTD.BO has a market cap of 1.2B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while PAUSHAKLTD.BO trades at ₹390.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas PAUSHAKLTD.BO's P/E ratio is 26.09. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to PAUSHAKLTD.BO's ROE of +0.08%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to PAUSHAKLTD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check PAUSHAKLTD.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, RESGEN.BO has a market cap of 1.2B. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while RESGEN.BO trades at ₹54.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas RESGEN.BO's P/E ratio is 14.13. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to RESGEN.BO's ROE of +0.14%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to RESGEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check RESGEN.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, CHEMCRUX.BO has a market cap of 998.9M. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while CHEMCRUX.BO trades at ₹66.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas CHEMCRUX.BO's P/E ratio is 48.18. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to CHEMCRUX.BO's ROE of +0.03%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to CHEMCRUX.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check CHEMCRUX.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, DEEPAKCHEM.BO has a market cap of 869M. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while DEEPAKCHEM.BO trades at ₹76.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas DEEPAKCHEM.BO's P/E ratio is 7.76. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to DEEPAKCHEM.BO's ROE of +0.19%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to DEEPAKCHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check DEEPAKCHEM.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, POLYCHEM.BO has a market cap of 836.4M. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while POLYCHEM.BO trades at ₹2,070.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas POLYCHEM.BO's P/E ratio is 4.48. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to POLYCHEM.BO's ROE of +0.40%. Regarding short-term risk, INDOAMIN.BO is more volatile compared to POLYCHEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.BO.Check POLYCHEM.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, PARAGON.NS has a market cap of 777.7M. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while PARAGON.NS trades at ₹39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas PARAGON.NS's P/E ratio is 9.08. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to PARAGON.NS's ROE of N/A. Regarding short-term risk, INDOAMIN.BO is less volatile compared to PARAGON.NS. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check PARAGON.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, ASHOKALC.BO has a market cap of 551.4M. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while ASHOKALC.BO trades at ₹119.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas ASHOKALC.BO's P/E ratio is -10.04. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to ASHOKALC.BO's ROE of +0.05%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to ASHOKALC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check ASHOKALC.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, SANGINITA.NS has a market cap of 495.5M. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while SANGINITA.NS trades at ₹19.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas SANGINITA.NS's P/E ratio is -14.60. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to SANGINITA.NS's ROE of -0.06%. Regarding short-term risk, INDOAMIN.BO is more volatile compared to SANGINITA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.BO.Check SANGINITA.NS's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, GARODCH.BO has a market cap of 482.7M. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while GARODCH.BO trades at ₹138.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas GARODCH.BO's P/E ratio is 76.21. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to GARODCH.BO's ROE of -1.14%. Regarding short-term risk, INDOAMIN.BO is more volatile compared to GARODCH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.BO.Check GARODCH.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, SHIVAAGRO.BO has a market cap of 396.8M. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while SHIVAAGRO.BO trades at ₹39.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas SHIVAAGRO.BO's P/E ratio is 180.50. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to SHIVAAGRO.BO's ROE of +0.00%. Regarding short-term risk, INDOAMIN.BO is less volatile compared to SHIVAAGRO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for INDOAMIN.BO.Check SHIVAAGRO.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, TRELCHE-B.BO has a market cap of 392.2M. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while TRELCHE-B.BO trades at ₹20.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas TRELCHE-B.BO's P/E ratio is N/A. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to TRELCHE-B.BO's ROE of N/A. Regarding short-term risk, INDOAMIN.BO is more volatile compared to TRELCHE-B.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.BO.Check TRELCHE-B.BO's competition here

INDOAMIN.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INDOAMIN.BO stands at 6.8B. In comparison, ZR2.BO has a market cap of 368.9M. Regarding current trading prices, INDOAMIN.BO is priced at ₹92.82, while ZR2.BO trades at ₹108.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INDOAMIN.BO currently has a P/E ratio of 9.55, whereas ZR2.BO's P/E ratio is 382.85. In terms of profitability, INDOAMIN.BO's ROE is +0.22%, compared to ZR2.BO's ROE of +0.00%. Regarding short-term risk, INDOAMIN.BO is more volatile compared to ZR2.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDOAMIN.BO.Check ZR2.BO's competition here